136 related articles for article (PubMed ID: 36443431)
1. Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML.
Pfeiffer T; Li Y; Ashcraft E; Karol SE; Rubnitz JE; Epperly R; Madden R; Mamcarz E; Obeng E; Qudeimat A; Sharma A; Srinivasan A; Suliman A; Talleur AC; Velasquez MP; Gottschalk S; Triplett BM; Naik S
Bone Marrow Transplant; 2023 Mar; 58(3):328-331. PubMed ID: 36443431
[No Abstract] [Full Text] [Related]
2. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.
Joshi M; Cook J; McCullough K; Nanaa A; Gangat N; Foran JM; Murthy HS; Kharfan-Dabaja MA; Sproat L; Palmer J; Pardanani A; Tefferi A; Begna K; Elliot M; Al-Kali A; Patnaik M; Shah MV; Hogan WJ; Litzow MR; Alkhateeb HB
Blood Cancer J; 2021 Mar; 11(3):49. PubMed ID: 33664234
[No Abstract] [Full Text] [Related]
3. Successful venetoclax and Actinomycin D-based treatment for relapsed acute myeloid leukemia post allogeneic hematopoietic cell transplantation.
Abou Dalle I; Bazarbachi A
Bone Marrow Transplant; 2021 Nov; 56(11):2626-2627. PubMed ID: 34376805
[No Abstract] [Full Text] [Related]
4. BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?
Pullarkat VA; Newman EM
Cancer Discov; 2016 Oct; 6(10):1082-1083. PubMed ID: 27698099
[TBL] [Abstract][Full Text] [Related]
5. Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy.
Ashby M; Fleming S; Teh TC; Tiong IS; Inam S; Curtis DJ; Patil S; Vassili C; Chua CC
Leuk Res; 2024 Jan; 136():107429. PubMed ID: 38008060
[No Abstract] [Full Text] [Related]
6. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.
Byrne M; Danielson N; Sengsayadeth S; Rasche A; Culos K; Gatwood K; Wyatt H; Chinratanalab W; Dholaria B; Ferrell PB; Fogo K; Goodman S; Jagasia M; Jayani R; Kassim A; Mohan SR; Savani BN; Strickland SA; Engelhardt BG; Savona M
Am J Hematol; 2020 Sep; 95(9):1006-1014. PubMed ID: 32390196
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
Zhao P; Ni M; Ma D; Fang Q; Zhang Y; Li Y; Huang Y; Chen Y; Chai X; Zhan Y; Li Y; Kang Q; Zhao M; Liu M; Zhang F; Huang S; Wen S; Deng B; Wang J
Ann Hematol; 2022 Jan; 101(1):119-130. PubMed ID: 34568973
[TBL] [Abstract][Full Text] [Related]
8. Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report.
Wang J; Zhu H; Miao K
Ann Hematol; 2024 May; 103(5):1775-1777. PubMed ID: 38556531
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of second allogeneic stem cell transplantation and anti-relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis.
Shumilov E; Hasenkamp J; Maulhardt M; Mazzeo P; Schmidt N; Boyadzhiev H; Jung W; Ganster C; Haase D; Koch R; Wulf G
Hematol Oncol; 2022 Oct; 40(4):763-776. PubMed ID: 35368106
[TBL] [Abstract][Full Text] [Related]
10. Ambulatory Hematopoietic Stem Cell Transplantation in Young Adults with Acute Myeloid Leukemia Treated with Venetoclax and Low Doses of Cytarabine: Report of Two Cases.
Flores-Jiménez JA; Pimentel-Morales MA; González-Ramella O; Vega-Cortés D; Zambrano-Velarde MÁ
J Adolesc Young Adult Oncol; 2019 Aug; 8(4):481-483. PubMed ID: 30835153
[TBL] [Abstract][Full Text] [Related]
11. Exciting times ahead for older patients with acute myeloid leukemia: azacitidine and venetoclax followed by allogeneic hematopoietic cell transplantation.
Bazarbachi A
Bone Marrow Transplant; 2022 Feb; 57(2):147-148. PubMed ID: 34645927
[No Abstract] [Full Text] [Related]
12. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
DiNardo CD; Lachowiez CA; Takahashi K; Loghavi S; Xiao L; Kadia T; Daver N; Adeoti M; Short NJ; Sasaki K; Wang S; Borthakur G; Issa G; Maiti A; Alvarado Y; Pemmaraju N; Montalban Bravo G; Masarova L; Yilmaz M; Jain N; Andreeff M; Jabbour E; Garcia-Manero G; Kornblau S; Ravandi F; Konopleva MY; Kantarjian HM
J Clin Oncol; 2021 Sep; 39(25):2768-2778. PubMed ID: 34043428
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
Bewersdorf JP; Derkach A; Gowda L; Menghrajani K; DeWolf S; Ruiz JD; Ponce DM; Shaffer BC; Tamari R; Young JW; Jakubowski AA; Gyurkocza B; Chan A; Xiao W; Glass J; King AC; Cai SF; Daniyan A; Famulare C; Cuello BM; Podoltsev NA; Roshal M; Giralt S; Perales MA; Seropian S; Cho C; Zeidan AM; Prebet T; Stein EM; Tallman MS; Goldberg AD; Stahl M
Leuk Lymphoma; 2021 Dec; 62(14):3394-3401. PubMed ID: 34477024
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia.
Sandhu KS; Dadwal S; Yang D; Mei M; Palmer J; Salhotra A; Al Malki M; Aribi A; Ali H; Khaled S; Forman SJ; Snyder D; Nakamura R; Stein AS; Marcucci G; Aldoss I; Pullarkat V
Biol Blood Marrow Transplant; 2020 Dec; 26(12):e322-e327. PubMed ID: 32866594
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.
Liu B; Narurkar R; Hanmantgad M; Zafar W; Song Y; Liu D
Front Med; 2018 Oct; 12(5):593-599. PubMed ID: 29785506
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
[TBL] [Abstract][Full Text] [Related]
18. Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
Jädersten M; Boriskina K; Lindholm C; Weström S; Cavelier L; Hellström-Lindberg E; Mielke S; Tobiasson M
Leuk Lymphoma; 2022 Mar; 63(3):755-758. PubMed ID: 34775885
[No Abstract] [Full Text] [Related]
19. Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
Andreani G; Dragani M; Serra A; Nicoli P; De Gobbi M; Cilloni D
Am J Hematol; 2019 Feb; 94(2):E48-E50. PubMed ID: 30431666
[No Abstract] [Full Text] [Related]
20. Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial.
Amit O; On YB; Perez G; Shargian-Alon L; Yeshurun M; Ram R
Ann Hematol; 2021 Mar; 100(3):817-824. PubMed ID: 33442793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
